Viking Therapeutics, Inc. Current Liabilities
Viking Therapeutics, Inc. (VKTX) had Current Liabilities of $109.66 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-29
- 2026-06-30: Liabilities, Current $109.66M.
- 2026-03-31: Liabilities, Current $106.33M.
- 2025-12-31: Liabilities, Current $76.67M.
- 2025-09-30: Liabilities, Current $26.07M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $109.66M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $106.33M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $76.67M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $26.07M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $31.98M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | $19.57M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $27.41M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $25.68M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $25.09M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $32.77M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $19.14M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $13.40M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $13.48M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $15.65M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $21.95M 10-K · filed 2024-02-07 | |
| 2022-09-30 | $14.06M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $14.86M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $11.27M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $8.78M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $11.35M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $12.87M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $12.92M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $12.13M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $9.71M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $9.05M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $8.54M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $6.78M 10-K · filed 2021-02-17 | |
| 2019-09-30 | $6.19M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $5.63M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $4.92M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $4.55M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $4.74M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $4.11M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $6.34M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $8.66M 10-K · filed 2019-03-13 | $8.66M 10-K · filed 2018-03-07 |
| 2017-09-30 | $9.61M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $7.73M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $3.38M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $6.48M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $6.08M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $5.74M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $1.92M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $1.98M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $5.72M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $4.88M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $27.71M 10-Q · filed 2015-06-12 | |
| 2014-12-31 | $22.52M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |